110 related articles for article (PubMed ID: 3541792)
1. [Phase II study of prednimustine in follicular lymphoma and chronic lymphocytic leukemia].
Ito Y; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ueno K; Imajou K; Miyaoka K; Ozeki H
Gan To Kagaku Ryoho; 1987 Jan; 14(1):173-8. PubMed ID: 3541792
[TBL] [Abstract][Full Text] [Related]
2. [Phase II study of chlorambucil in patients with hematological malignancies].
Inoue K; Ogawa M; Horikoshi N; Mukaiyama T; Itoh Y; Imajoh K; Ozeki H; Nagamine D; Shinagawa K
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2672-5. PubMed ID: 3307632
[TBL] [Abstract][Full Text] [Related]
3. [Early phase II trial of bestrabucil in hematological malignancies].
Nagura E; Ohno R; Yamada K; Akao Y; Naito K; Nishikawa M; Tanaka H; Shirakawa S; Ono Y; Ezaki K
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2216-22. PubMed ID: 3459398
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.
Pedersen-Bjergaard J; Hansen MM; Geisler CH; Nissen NI
Acta Med Scand; 1980; 207(3):215-20. PubMed ID: 6989170
[TBL] [Abstract][Full Text] [Related]
5. Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria.
Gandara DR; George CB; Ries CA; Koretz MM; Lewis JP
Cancer Chemother Pharmacol; 1987; 19(2):165-8. PubMed ID: 3568275
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of prednimustine in children with recurrent cancer: a Children's Cancer Study Group report.
Gaynon PS; Baum ES; Krivit W; Hammond D
Cancer Treat Rep; 1982 Jul; 66(7):1583-4. PubMed ID: 6284362
[No Abstract] [Full Text] [Related]
7. [Clinical trial of bestrabucil (KM 2210) on hematopoietic malignancies].
Nishikawa M; Uemura Y; Matsuoka N; Ohno T; Katayama N; Tomeoku M; Kobayashi T; Kita K; Tanaka H; Minami N
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2155-9. PubMed ID: 3521494
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.
Ideström K; Kimby E; Björkholm M; Mellstedt H; Engstedt L; Gahrton G; Johansson B; Killander D; Robérts KH; Stalfelt AM; Udén AM; Wadman B; Wählby S
Eur J Cancer Clin Oncol; 1982 Nov; 18(11):1117-23. PubMed ID: 6897633
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
10. A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C.
Biomedicine; 1977 Jun; 27(4):158-61. PubMed ID: 329910
[TBL] [Abstract][Full Text] [Related]
11. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group.
Gandara DR; Wold HG; Redmond J; Kohler M; Reynolds R; Wong P; Forsythe J; Fisher K; Lewis B
Semin Oncol; 1986 Mar; 13(1 Suppl 1):14-8. PubMed ID: 3952517
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Prednimustine (Leo 1031) in chronic lymphatic leukemia].
Lutz D; Böhnel J
Osterr Z Onkol; 1977; 3(5-6):155-9. PubMed ID: 323777
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.
Gandara DR; Ries CA; Schiff SA; George CB; Lewis JP; Koretz MM; Carter SK
Cancer Chemother Pharmacol; 1982; 9(1):10-2. PubMed ID: 7139848
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of prednimustine in glioblastoma multiforme.
Andersen J; Christensen L; Kongsholm H
Cancer Treat Rep; 1984 May; 68(5):795-7. PubMed ID: 6327038
[TBL] [Abstract][Full Text] [Related]
15. Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution.
Roncadin M; Arcicasa M; Zagonel V; Bortolus R; Valeri P; Pinto A; De Paoli A; Franchin G; Carbone A; Trovò MG
Cancer; 1994 Aug; 74(3):978-84. PubMed ID: 8039128
[TBL] [Abstract][Full Text] [Related]
16. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
[TBL] [Abstract][Full Text] [Related]
18. Clinical response to busramustine (KM-2210) in chronic lymphocytic leukemia: a pilot evaluation of estrogen receptor in relation to its therapeutic effect.
Nishikawa M; Uemura Y; Komada F; Ohno T; Katayama N; Shirakawa S
Jpn J Clin Oncol; 1988 Dec; 18(4):327-33. PubMed ID: 3204682
[TBL] [Abstract][Full Text] [Related]
19. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
Bremer K
J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
